Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients

Microbes Infect. 2022 Sep;24(6-7):104976. doi: 10.1016/j.micinf.2022.104976. Epub 2022 Apr 4.

Abstract

One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2-specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean ± SD; TM = 1917,21 ± 1384,49; HBD = 2039,81 ± 1064,44; p = 0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p < 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty.

Keywords: Humoral response; Sars-Cov 2; Thalassemia major; Vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Humans
  • Immunity, Humoral
  • RNA, Viral
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus / genetics
  • Vaccination
  • Vaccines, Synthetic
  • Viral Vaccines*
  • beta-Thalassemia*
  • mRNA Vaccines

Substances

  • Antibodies, Viral
  • RNA, Viral
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Synthetic
  • Viral Vaccines
  • mRNA Vaccines
  • spike protein, SARS-CoV-2
  • BNT162 Vaccine